Summary
Upsher-Smith Laboratories, Inc. (Upsher-Smith) is a pharmaceutical company that develops, manufactures and distributes consumer and CNS products. The company’s consumer products include restoring body lotion, foot cream, moisturizing body lotion, hydrating body cream, vitamin D3, folic acid, vitamins B6 and B12, and dietary supplement. It offers CNS products such as carbamazepine tablets, divalproex sodium delayed-release tablets, lamotrigine tablets, phenytoin sodium extended-release capsules, topiramate capsules and valproic acid capsules. Upsher-Smith provides products for therapeutic areas such as central nervous system disorders and specialty indications. The company’s products serve patients, physicians, pharmacists, and healthcare organizations. Upsher-Smith is headquartered in Maple Grove, Minnesota, the US.
Upsher-Smith Laboratories, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Proximagen Acquires Two CNS Drug Development Programmes From GlaxoSmithKline 11
Partnerships 13
Proximagen Enters into Co-Development Agreement with Saniona 13
MRC Technology Enters into Co-Development Agreement with Proximagen 14
Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 15
Proximagen And Altacor Enter Into R&D Agreement For Treatment Of Glaucoma 16
H. Lundbeck Enters Into Co-Development Agreement With Proximagen 18
Novo Nordisk Enters Into Co-Marketing Agreement With Upsher-Smith Labs 19
Proximagen Neuroscience Enters Into A Collaboration With The National Institutes of Health 20
Licensing Agreements 22
F. Hoffmann-La Roche Entered into Licensing Agreement with Proximagen 22
Ligand Pharma Enters Into Licensing Agreement With Proximagen Group 23
Proximagen Group Enters Into Licensing Agreement With BrainCells 24
Upsher-Smith Labs Enters Into Licensing Agreement With Ikano Therapeutics 26
Upsher-Smith Labs Enters Into Licensing Agreement With Proximagen 27
Asset Transactions 29
Vertical Pharma Acquires Portfolio Of Womens Health Products From Upsher-Smith Labs 29
Acquisition 31
Upsher-Smith Completes Acquisition Of Remaining 84% Stake In Proximagen For Up To US$555 Million 31
Upsher-Smith Labs Acquires Additional 1.22% Stake In Proximagen 34
Proximagen Neuroscience Acquires Minster Pharma 35
Upsher-Smith Laboratories, Inc. - Key Competitors 37
Key Employees 38
Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Tables
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Key Facts 1
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Upsher-Smith Laboratories, Inc., Deals By Therapy Area, 2010 to YTD 2016 8
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Proximagen Acquires Two CNS Drug Development Programmes From GlaxoSmithKline 11
Proximagen Enters into Co-Development Agreement with Saniona 13
MRC Technology Enters into Co-Development Agreement with Proximagen 14
Upsher-Smith Labs Enters Into Development Agreement With Lundbeck 15
Proximagen And Altacor Enter Into R&D Agreement For Treatment Of Glaucoma 16
H. Lundbeck Enters Into Co-Development Agreement With Proximagen 18
Novo Nordisk Enters Into Co-Marketing Agreement With Upsher-Smith Labs 19
Proximagen Neuroscience Enters Into A Collaboration With The National Institutes of Health 20
F. Hoffmann-La Roche Entered into Licensing Agreement with Proximagen 22
Ligand Pharma Enters Into Licensing Agreement With Proximagen Group 23
Proximagen Group Enters Into Licensing Agreement With BrainCells 24
Upsher-Smith Labs Enters Into Licensing Agreement With Ikano Therapeutics 26
Upsher-Smith Labs Enters Into Licensing Agreement With Proximagen 27
Vertical Pharma Acquires Portfolio Of Womens Health Products From Upsher-Smith Labs 29
Upsher-Smith Completes Acquisition Of Remaining 84% Stake In Proximagen For Up To US$555 Million 31
Upsher-Smith Labs Acquires Additional 1.22% Stake In Proximagen 34
Proximagen Neuroscience Acquires Minster Pharma 35
Upsher-Smith Laboratories, Inc., Key Competitors 37
Upsher-Smith Laboratories, Inc., Key Employees 38
Upsher-Smith Laboratories, Inc., Other Locations 39
Upsher-Smith Laboratories, Inc., Subsidiaries 39
List of Figures
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Upsher-Smith Laboratories, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
